Supplemental Table 1. Characteristics of Study Population by reliability of MRE data

Variable	Excluded (N = 17)	Included (N=90)	P value
Age, mean (SD), y	12.5 (3.1)	13.1 (2.4)	0.4873
Sex, N (%)			0.1459
Boys	9 (52.9%)	66 (73.3%)	
Girls	8 (47.1%)	24 (26.6%)	
Race, N (%)			0.4277
White	11 (64.7%)	46 (51.1%)	
Other	6 (35.3%)	44 (48.9%)	
Ethnicity, N (%)			0.1955
Hispanic	14 (82.4%)	83 (92.2%)	
Non-Hispanic	3 (17.6%	7 (7.8%)	
Weight, mean (SD), Kg	78.9 (29.8)	80.5 (24.0)	0.5423
Height, mean (SD), cm	156.0 (14.3)	160.4 (12.3)	0.2661
BMI (Kg/m^2), mean (SD)	31.3 (6.9)	30.7 (6.2)	0.7884
BMI Z score	2.3 (0.4)	2.1 (0.4)	0.1781
ALT, median (range), U/L	83.0 (34 - 675)	63.0 (17 - 811)	0.0443
AST, median (range), U/L	56.0 (20 - 265)	40.0 (16 - 364)	0.1250
GGT, median (range), U/L	39 (19 - 224)	30.5 (11 - 407)	0.0524
Platelet count, median (range), x 10^9/L	277.0 (167 - 477)	280.0 (69 - 430)	0.9118
Steatosis grade, N (%)			0.3827
Grade 0	2 (11.8%)	4 (4.4%)	
Grade 1	3 (17.6%)	28 (31.1%)	
Grade 2	3 (17.6%)	20 (22.2%)	
Grade 3	9 (52.9%)	38 (42.2%)	
Lobular Inflammation, N (%)			0.789
Grade 0-1	6 (35.3%)	38 (42.2%)	
Grade 2-3	11 (64.7%)	52 (57.8%)	
Portal Inflammation, N (%)			8e-04
Grade 0	1 (5.9%)	42 (46.7%)	
Grade 1	13 (76.5%)	45 (50.0%)	
Grade 2	3 (17.6%)	3 (3.3%)	
Hepatocellular Ballooning, N (%)			.1736
Grade 0	12 (70.6%)	46 (51.1%)	
Grade 1	3 (17.6%)	36 (40.0%)	
Grade 2	2 (11.8%)	8 (8.9%)	
NASH diagnosis, N (%)			0.035
None/NAFLD	3 (17.6%)	41 (45.6%)	
Borderline/Definite NASH	14 (82.4%)	49 (54.4%)	
Fibrosis Stage, N (%)			<0.0001
Stages 0-2	8 (47.1%)	84 (93.3%)	
Stages 3-4	9 (52.9%)	6 (6.7%)	